REMEDi4ALL launches to drive the repurposing of medicines in Europe

Press Release SCAI /

The EU-funded project REMEDi4ALL will make a major leap forward in drug repurposing, or finding new therapeutic options for existing drugs, in areas with high unmet medical needs.

SANK AUGUSTIN.   The three Fraunhofer institutes participating in REMEDi4ALL, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Institute for Cell Therapy and Immunology IZI, and Fraunhofer Institute for Algorithms and Scientific Computing SCAI, combine expertise in the realization of in-silico and in-vitro driven drug repurposing programs, the design of predictive in-vivo models, the execution of clinical trials and the application of computational science with a focus on algorithm development for the analysis of drug discovery data.

Fraunhofer SCAI brings its expertise from the Human Brain Pharmacome (HBP) project into REMEDI4ALL. With Fraunhofer ITMP, SCAI has developed a drug-repurposing approach that combines in silico analyses and in vitro screenings. Another result of HBP was the development of a drug- and mechanism-oriented model. The HBP was used to mine data related to drugs and targets to generate a hypothesis.

SCAI will add tools and data to a sustainable repository of open-source AI tools and open access datasets for supporting user-driven in silico discovery applications in Work Package 4 (Research data, tools, and in silico discovery). Examples are the following pharmacomes: Alzheimer's Disease, Parkinson's Disease, and COVID-19 – accessible via the Biomedical Knowledge Miner (BiK>Mi).

Please click here for the press release of the Fraunhofer ITMP.


Dr. Marc Jacobs
Business Area Bioinformatics
Fraunhofer Institute for Algorithms and Scientific Computing SCAI
Schloss Birlinghoven 1, 53757 Sankt Augustin, Germany
Phone: +49 2241 14-4013